EADV 2020

29th EADV Congress

Real-world data on brodalumab affirm efficacy and fast onset of action

Biologic psoriasis treatment and COVID-19 risk: still a matter of debate

Hidradenitis suppurativa: beware of psychiatric comorbidities and suicidal ideation

IL-23p19 class antibody efficacious in psoriasis management

Topical pan-JAK inhibitor achieved efficacy and fast onset in chronic hand eczema

JAK1 inhibition successful in hidradenitis suppurativa

Secukinumab: a new management option for paediatric severe psoriasis

Sleep quality of partners of psoriasis patients

Oral prevention of skin cancer

Low early PASI response could predict favourable outcomes for psoriasis patients on biologics

Discontinuation of omalizumab during COVID-19 pandemic associated with poor outcomes for chronic spontaneous urticaria

Impact of personal protective equipment on acne vulgaris and rosacea

New hope for epidermolysis bullosa patients

Oral JAK 1 inhibitor leads to fast itch relieve and remarkable skin clearance in AD

Efficacious non-steroidal topical for psoriasis

Zinc oxide coated socks against foot odour

Topical TYK2/JAK 1 inhibitor effective and tolerable in mild-to-moderate AD

Risky sexual behaviour and STIs on the rise despite the pandemic

Top image: @ iStockPhoto: ipopba

The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.